Company
Protalix BioTherapeutics, Inc.
Headquarters: Karmiel, Israel
Founded: 1993
Employees: 207
CEO: Mr. Dror Bashan
Market Cap
₪292.9 Million
ILS as of Jan. 1, 2023
US$83.6 Million
Protalix BioTherapeutics, Inc. Categories
Israel Healthcare BiotechnologyIsrael Healthcare Israel Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Protalix BioTherapeutics, Inc. has the following listings and related stock indices.
Stock: TASE: PLX wb_incandescent
Stock: NYSE: PLX wb_incandescent
Stock: FSX: PBDA wb_incandescent
Product & Services
Elelyso
Key People
Founder(s): Yoseph Shaaltiel
Shlomo Yanai (Interim Chairman) Moshe Manor (CEO)
Financials
Revenue: $11.51 million (2013)
Total assets: $113.33 million (2013)